Soft Glycopyrrolate Topical Formulation for Stable Hyperhidrosis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticholinergic compounds used for treating hyperhidrosis face challenges such as systemic side effects, instability in topical formulations, and the need for repeated injections, making them unsuitable for long-term use and pediatric patients.
Innovation Solution
A stable, pharmaceutically acceptable topical formulation comprising a soft anticholinergic ester analog of glycopyrrolate in anhydrous ethanol with gelling agents and citric acid, minimizing transesterification and hydrolysis, and providing a preservative-free composition for effective sweat reduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical anticholinergic agents are administered to treat hyperhidrosis, then sweat reduction is achieved, but systemic side effects occur which limit safe dosage
Solution Approach 1:
The patent modifies the chemical structure of anticholinergic agents by creating soft ester analogs with specific ester linkages that enable rapid hydrolysis in systemic circulation. This parameter change in molecular structure allows the drug to maintain therapeutic activity at the application site while being quickly converted to inactive metabolites upon systemic absorption, thereby reducing systemic side effects
Solution Approach 2:
The patent introduces ester linkages as intermediary chemical bonds that facilitate controlled metabolism. These ester bonds act as metabolic handles that enable the drug to be rapidly hydrolyzed by esterases in the bloodstream, serving as an intermediary mechanism between active drug delivery and safe elimination, thus reducing systemic exposure and side effects
2Reliability
If soft anticholinergic ester analogs are formulated topically, then therapeutic index is increased, but formulation stability is compromised due to transesterification and hydrolysis
Solution Approach 1:
The patent employs anhydrous conditions as an inert environment that prevents unwanted hydrolysis and transesterification reactions. By formulating the soft ester analogs in water-free bases and using anhydrous preparation methods, the formulation creates a chemically inert atmosphere that preserves ester bond integrity during storage, maintaining formulation stability while preserving the rapid hydrolysis capability upon systemic absorption
Solution Approach 2:
The patent utilizes short-chain esters that are designed to be rapidly metabolized and eliminated, analogous to disposable components. These ester linkages are intentionally created as temporary, labile bonds that serve their purpose of drug delivery and then quickly degrade into harmless, easily eliminated metabolites, allowing for safe repeated applications
3Reliability
If conventional anticholinergics are used for hyperhidrosis treatment, then sweat reduction is achieved, but repeated injections or frequent applications are required
Solution Approach 1:
The patent creates a periodic action pattern where the soft ester analogs are applied topically and then rapidly converted to inactive metabolites through controlled hydrolysis. This periodic metabolism and elimination cycle allows for sustained therapeutic effect at the application site with rapid clearance, enabling effective repeated applications at appropriate intervals without cumulative toxicity, thus reducing the need for frequent treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves significant sweat reduction for up to 48 hours with minimal systemic side effects, maintaining stability and efficacy, and reducing sweat production by 25-99% for treating hyperhidrosis.
Implementation Method 1
quickly metabolized into their designed-in, inactive metabolite upon entering the systemic circulation
Implementation Method 2
minimizing transesterification and hydrolysis
Implementation Method 3
minimizing transesterification and hydrolysis
Data Source
AI summary
Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.